發(fā)布時(shí)間：2018-03-27 15:49

  本文選題：心房顫動(dòng)　切入點(diǎn)：導(dǎo)管射頻消融　出處：《Journal of Zhejiang University-Science B(Biomedicine & Biotechnology)》2017年11期

【摘要】：目的:評(píng)估非瓣膜病性房顫患者應(yīng)用利伐沙班抗凝治療相較華法林的代謝獲益,及利伐沙班應(yīng)用的安全性和有效性。創(chuàng)新點(diǎn):首次研究利伐沙班對(duì)房顫射頻消融術(shù)后患者代謝水平影響,評(píng)估利伐沙班相較華法林抗凝治療的代謝獲益。方法:前瞻性入選2014年4月至7月共60例行經(jīng)皮房顫導(dǎo)管射頻消融術(shù)患者,隨機(jī)分為利伐沙班治療組和華法林治療組。在術(shù)后15、30、60和90天檢測(cè)代謝指標(biāo)(包括血清總蛋白、白蛋白、球蛋白和高密度脂蛋白(HDL)等)變化,并隨訪出血、卒中和系統(tǒng)性栓塞事件等發(fā)生情況。結(jié)論:服用利伐沙班抗凝治療患者在隨訪期間血清總蛋白、白蛋白、球蛋白和HDL水平較術(shù)前均顯著升高,而華法林治療組患者各項(xiàng)代謝指標(biāo)呈先下降、后上升趨勢(shì)。兩組均沒(méi)有發(fā)生死亡和栓塞事件,出血并發(fā)癥發(fā)生率亦無(wú)明顯差異。研究結(jié)果表明,非瓣膜病性房顫患者經(jīng)導(dǎo)管射頻消融術(shù)后接受利伐沙班抗凝具有代謝方面獲益,與華法林相比兩者在安全性和有效性方面無(wú)明顯差異,研究結(jié)果可為臨床選擇合適抗凝方案提供參考。
[Abstract]:Objective: to evaluate the metabolic benefits of warfarin in patients with non-valvular atrial fibrillation treated with rivastaben anticoagulant therapy. Innovation: the effect of rivastabine on the metabolic level of patients with atrial fibrillation after radiofrequency ablation was studied for the first time. Methods: a total of 60 patients undergoing percutaneous catheter radiofrequency ablation of atrial fibrillation from April to July 2014 were prospectively selected to evaluate the metabolic benefits of rivastaban compared with warfarin anticoagulant therapy. The patients were divided into two groups randomly. The metabolic indexes (including serum total protein, albumin, globulin and high density lipoprotein (HDLL)) were measured on the 15th day, 30th day and 90th day after operation, and the patients were followed up with bleeding. Conclusion: the levels of serum total protein, albumin, globulin and HDL in patients treated with rivastaban anticoagulant therapy were significantly higher than those before operation. However, the metabolic indexes of warfarin group decreased first, then increased. There was no death or embolism, and there was no significant difference in the incidence of bleeding complications between the two groups. Patients with non-valvular atrial fibrillation received rivastaben after radiofrequency catheter ablation had metabolic benefits. There was no significant difference in safety and efficacy between the two groups compared with warfarin. The results can provide a reference for clinical selection of appropriate anticoagulant regimen.
【作者單位】： Department
【分類號(hào)】：R541.75

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張衛(wèi)茹;非瓣膜病性房顫的抗凝治療[J];中國(guó)醫(yī)師雜志;2002年02期

2 許俊堂;;非瓣膜病性房顫的抗栓療法[J];中國(guó)醫(yī)刊;2006年09期

3 陸學(xué)林;張建;鄭楓;張洪濤;;房顫患者233例抗凝治療分析[J];醫(yī)藥論壇雜志;2010年19期

4 歐孝琪;鄭東鵬;;房顫的抗凝治療[J];西藏醫(yī)藥雜志;2006年01期

5 馬景梅,王梅;心臟非瓣膜病性房顫致腦栓塞的臨床特點(diǎn)及其治療[J];泰山醫(yī)學(xué)院學(xué)報(bào);2002年01期

6 呂澤峰;胺碘酮治療部分非瓣膜病性房顫的療效觀察[J];廣西醫(yī)學(xué);2000年04期

7 朱平先,王合森,黃灶林,黃英照;老年非瓣膜病性房顫患者血栓形成干預(yù)研究[J];介入放射學(xué)雜志;2004年S2期

8 范莉娟;吳英;;老年非瓣膜病性房顫華法林抗凝治療臨床分析[J];心腦血管病防治;2007年04期

9 馬云青;鄭澤琪;;不同抗凝強(qiáng)度的華法林對(duì)非瓣膜病性房顫抗栓的療效和安全性[J];江西醫(yī)學(xué)院學(xué)報(bào);2007年05期

10 劉迎春,張梅勝;非瓣膜病性房顫與缺血性腦卒中的關(guān)系[J];包頭醫(yī)學(xué)院學(xué)報(bào);2002年04期

，

本文編號(hào)：1672180